Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
RSS

DDP-733 produces statistically significant clinical response rate in IBS-c

Feb. 15, 2007

TG-4040 studied in phase I trial for chronic HCV

Feb. 15, 2007

Long-acting octreotide to be investigated in polycystic liver disease

Feb. 15, 2007

Recent Pfizer patent discloses novel therapeutic agents for gastrointestinal disorders

Feb. 14, 2007

Novel treatment options for HCV infection reported in recent patents

Feb. 14, 2007

Gilead and Achillion advance NS4A antagonist collaboration

Feb. 13, 2007

Tibotec begins phase I study with HCV protease inhibitor

Feb. 12, 2007

New therapeutic agents for hepatitis C virus (HCV) infection reported in recent Gilead patent

Feb. 12, 2007

Migenix updates status of Schering-Plough's license option

Feb. 9, 2007

New treatments for gastrointestinal disorders claimed in recent patent literature

Feb. 9, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026